BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17603048)

  • 21. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity. Results from the European multi-centre STORM trial. Sibutramine Trial of Obesity Reduction and Maintenance.
    Hansen D; Astrup A; Toubro S; Finer N; Kopelman P; Hilsted J; Rössner S; Saris W; Van Gaal L; James W; Goulder M;
    Int J Obes Relat Metab Disord; 2001 Apr; 25(4):496-501. PubMed ID: 11319653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity.
    Fanghänel G; Cortinas L; Sánchez-Reyes L; Berber A
    Int J Obes Relat Metab Disord; 2000 Feb; 24(2):144-50. PubMed ID: 10702763
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial.
    Berkowitz RI; Wadden TA; Tershakovec AM; Cronquist JL
    JAMA; 2003 Apr; 289(14):1805-12. PubMed ID: 12684359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population.
    Cuellar GE; Ruiz AM; Monsalve MC; Berber A
    Obes Res; 2000 Jan; 8(1):71-82. PubMed ID: 10678261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
    James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
    Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors.
    McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K;
    J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sibutramine plus meal replacement therapy for body weight loss and maintenance in obese patients.
    Early JL; Apovian CM; Aronne LJ; Fernstrom MH; Frank A; Greenway FL; Heber D; Kushner RF; Cwik KM; Walch JK; Hewkin AC; Blakesley V
    Obesity (Silver Spring); 2007 Jun; 15(6):1464-72. PubMed ID: 17557984
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction.
    Zannad F; Gille B; Grentzinger A; Bruntz JF; Hammadi M; Boivin JM; Hanotin C; Igau B; Drouin P
    Am Heart J; 2002 Sep; 144(3):508-15. PubMed ID: 12228789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP
    Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
    Caterson ID; Finer N; Coutinho W; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Legler UF; Shepherd GM; Rode RA; Perdok RJ; Renz CL; James WP;
    Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of the month. After the storm over central anorectic agents, the "STORM" study of sibutramine].
    Scheen AJ
    Rev Med Liege; 2001 Jan; 56(1):56-8. PubMed ID: 11256141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of weight loss on the metabolic syndrome.
    Phelan S; Wadden TA; Berkowitz RI; Sarwer DB; Womble LG; Cato RK; Rothman R
    Int J Obes (Lond); 2007 Sep; 31(9):1442-8. PubMed ID: 17356528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
    Wang TF; Pei D; Li JC; Tsai WC; Tsai CC; Yao CY; Chang ET; Hsieh MC; Su KY; Kuo SW
    Int J Clin Pract; 2005 Jul; 59(7):746-50. PubMed ID: 15963197
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of sibutramine treatment in obese adolescents: a randomized trial.
    Berkowitz RI; Fujioka K; Daniels SR; Hoppin AG; Owen S; Perry AC; Sothern MS; Renz CL; Pirner MA; Walch JK; Jasinsky O; Hewkin AC; Blakesley VA;
    Ann Intern Med; 2006 Jul; 145(2):81-90. PubMed ID: 16847290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
    Halpern A; Leite CC; Herszkowicz N; Barbato A; Costa AP
    Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):98-102. PubMed ID: 12118266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
    Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.